

3rd ACTION Scientific Workshop

TRANSFORMATIVE STRATEGIES FOR THE DEVELOPMENT OF NEW PAIN THERAPIES

Co-Chairs: Allan Basbaum, Robert Dworkin, Frank Porreca, and Dennis Turk

June 23, 2014

SESSION I: Genetics, epigenetics, and pharmacogenomics

- Co-Chairs: Allan Basbaum and William Maixner

8:30-9:30 am

Keynote address: Epigenetics and pain

- Steve McMahon

9:30-10:00 am

Laura Stone: SPARC and back pain

10:00-10:30 am

David Clark: Genetic and epigenetic contributions to persistent pain

10:30-11:00 am

Break

11:00-11:30 pm

Chas Bountra: Epigenetic probes for pain and neuropsychiatric disorders

11:30-12:00 pm

Jordana Bell: DNA Methylation studies in twins

12:00-12:30 pm

William Maixner: Genetics, pharmacogenomics, and the translational clock

12:30-1:30 pm

Lunch

1:30-3:00 pm

Q & A and panel discussion

- Co-Chairs: Allan Basbaum and William Maixner
- Jordana Bell, Chas Bountra, David Clark, Sharon Hertz, Steve McMahon, Laura Stone

3:00-3:30 pm

Break

SESSION II: Imaging in translation

- Chair: Frank Porreca

3:30-4:00 pm

M. Catherine Bushnell: From mice to men: the role of brain imaging in translational pain research

4:00-4:30 pm

Yves De Koninck: Optogenetics

4:30-5:00 pm

Q & A

- Catherine Bushnell and Yves de Koninck

June 24, 2014

SESSION III: Transformative approaches to identifying analgesic treatments: stem cells, gene therapy, and toxins

- Co-Chairs: Allan Basbaum and Frank Porreca

8:30-9:30 am

Keynote address: Human pluripotent stem cells

- Clive Svendsen

9:30-10:00 am

Allan Basbaum: Stem cells and pain

10:00-10:30 am

Joseph Glorioso: Gene therapy potential in pain

10:30-11:00 am

Break

11:00-11:30 am

Baldomero (Toto) Olivera: Toxins for pain

11:30-12:30 pm

Q & A and Panel Discussion

- Co-Chairs: Frank Porreca and Allan Basbaum
- Allan Basbaum, Joseph Glorioso, Baldomero Olivera, Clive Svendsen

12:30-1:30 pm

Lunch

SESSION IV: Translational analgesic success stories

- Co-Chairs: Bob Dworkin and Dennis Turk

1:30-2:00 pm

Andrew Rice: Preclinical and clinical studies of angiotensin II receptor blockers

2:00-2:30 pm

Nathaniel Katz: Preclinical and clinical studies of anti-NGF antibodies

2:30-3:00 pm

Lars Edvinsson: Preclinical studies of anti-CGRP agents

3:00-3:30 pm

Break

3:30-4:00 pm

Marcelo Bigal: Clinical studies of anti-CGRP agents

4:00-5:00 pm

Q & A and Panel Discussion

- Co-Chairs: Bob Dworkin and Dennis Turk
- Marcelo Bigal, Lars Edvinsson, Nathaniel Katz, Bob Rappaport, Andrew Rice